However, little is known about where in the United States these workforce shortages are the greatest. To address, clinicians and public health experts have created new telemedicine infrastructures and innovated artificial intelligence. 1 This increasing demand for ROP screening and treatment and concomitant shortage of ROP treating physicians represents one of the biggest public health challenges of ROP- the workforce crisis. Nevertheless, when surveyed by Vartanian et al., one in 10 neonatal intensive care unit (NICU) directors report difficulty maintaining or retaining ROP services, with a large percentage citing lack of access to trained physicians. Soares discuss her impactful work on the geographic access to retinopathy of prematurity (ROP) treatment with us, which she presented at the Retina Society Meeting in Chicago.Ĭan you tell our readers about your study?Īs many readers know, the incidence and severity of ROP is rising in the United States. Soares has done impressive work examining risk factors for access to care for retinal diseases through various projects. Soares from Wills Eye Hospital, who is the 2021 recipient of the Retina Society Fellowship Research Award. All rights reserved.Mid Atlantic Retina at Wills Eye HospitalĬongratulations to Dr. Proprietary or commercial disclosures may be found after the references.Īge-related macular degeneration Brimonidine Geographic atrophy Implant Nonexudative.Ĭopyright © 2023 American Academy of Ophthalmology. The study was terminated early because of the lower-than-expected GA progression rate in the sham/control group. The primary efficacy endpoint at 24 months was not met, but there was a numeric trend for reduction in GA progression at 24 months compared with sham treatment. Multiple intravitreal administrations of Brimo DDS (Gen 2) were well tolerated. Treatment-related adverse events were usually related to the injection procedure. Exploratory analysis showed numerically smaller loss over time in retinal sensitivity assessed with scotopic microperimetry with Brimo DDS than with sham (P = 0.053 at month 24). At month 30, GA area change from baseline was 4.09 (0.15) mm 2 with Brimo DDS (n = 49) versus 4.52 (0.15) mm 2 with sham (n = 46), a reduction of 0.43 mm 2 (10%) with Brimo DDS compared with sham (P = 0.033). Least squares mean (standard error) GA area change from baseline at month 24 (primary endpoint) was 3.24 (0.13) mm 2 with Brimo DDS (n = 84) versus 3.48 (0.13) mm 2 with sham (n = 91), a reduction of 0.25 mm 2 (7%) with Brimo DDS compared with sham (P = 0.150). The study was terminated early, at the time of the planned interim analysis, because of a slow GA progression rate (∼ 1.6 mm 2/year) in the enrolled population.
The primary efficacy endpoint was GA lesion area change from baseline in the study eye, assessed with fundus autofluorescence imaging, at month 24. Patients diagnosed with GA secondary to AMD and multifocal lesions with total area of > 1.25 mm 2 and ≤ 18 mm 2 in the study eye.Įnrolled patients were randomized to treatment with intravitreal injections of 400-μg Brimo DDS (n = 154) or sham procedure (n = 156) in the study eye every 3 months from day 1 to month 21. To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).Ī phase IIb, randomized, multicenter, double-masked, sham-controlled, 30-month study (BEACON). 11 Eye Care Development, Allergan, an AbbVie company, Irvine, California.10 Data and Statistical Sciences, Allergan, an AbbVie company, Irvine, California.8 Department of Ophthalmology, University of Bonn, Bonn, Germany.7 Retina Consultants of Southern Colorado PC, Colorado Springs, Colorado.6 Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, and Department of Surgery (Ophthalmology), University of Melbourne, Melbourne, Australia Centre for Ophthalmology and Visual Science (incorporating Lions Eye Institute), the University of Western Australia, Nedlands, Western Australia, Australia.5 Mid Atlantic Retina, the Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.4 Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, and Department of Surgery (Ophthalmology), University of Melbourne, Melbourne, Australia.3 Centre Hospitalier Creteil, Service Universitaire d'Ophthalmologie, Creteil, France.Electronic address: 2 Department of Ophthalmology, University Vita-Salute Scientific Institute, Hospital San Raffaele, Milan, Italy. 1 Jacobs Retina Center, University of California San Diego, La Jolla, California.
0 kommentar(er)
